Vardenafil hcl

Vardenafil hcl

Levitra (vardenafil) belongs to a class of medications called phosphodiesterase (PDE) inhibitors. Vardenafil relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body. Includes Vardenafil indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse reactions, off-label uses and more. Learn about vardenafil usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives. Levitra (vardenafil hydrochloride) is an erectile dysfunction agent that works by blocking a certain enzyme (phosphodiesterase-PDE5) used to treat erectile dysfunction (impotence). Vardenafil belongs to a group of medicines, known as phosphodiesterase-5 (PDE-5) inhibitors, which are used to treat erectile dysfunction or pulmonary arterial hypertension. What is vardenafil? Vardenafil is used in adult men to treat erectile dysfunction (impotence). Vardenafil may also be used for purposes not listed in this medication guide. It is important that you tell all of your doctors that you take vardenafil. If you need emergency medical care for a heart problem, it is important that your doctor knows when you last took vardenafil. Vardenafil, sold under the brand name Levitra among others, is a medication that is used for treating erectile dysfunction. [1][2] It is a PDE5 inhibitor. [1] It is taken by mouth. Vardenafil is in a class of medications called phosphodiesterase (PDE) inhibitors. It works by increasing blood flow to the penis during sexual stimulation. This increased blood flow can cause an erection. Vardenafil does not cure erectile dysfunction or increase sexual desire. What is this medication? VARDENAFIL (var DEN a fil) treats erectile dysfunction (ED). It works by increasing blood flow to the penis, which helps to maintain an erection.

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*